- Home
- RDFN vs GYRE Comparison
RDFN vs GYRE Comparison
Compare RDFN & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDFN
- GYRE
- Stock Information
- Founded
- RDFN 2002
- GYRE 2002
- Country
- RDFN United States
- GYRE United States
- Employees
- RDFN N/A
- GYRE N/A
- Industry
- RDFN Real Estate
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- RDFN Finance
- GYRE Health Care
- Exchange
- RDFN Nasdaq
- GYRE Nasdaq
- Market Cap
- RDFN 1.1B
- GYRE 1.1B
- IPO Year
- RDFN 2017
- GYRE N/A
- Fundamental
- Price
- RDFN $8.22
- GYRE $9.73
- Analyst Decision
- RDFN Hold
- GYRE
- Analyst Count
- RDFN 11
- GYRE 0
- Target Price
- RDFN $9.43
- GYRE N/A
- AVG Volume (30 Days)
- RDFN 4.1M
- GYRE 143.3K
- Earning Date
- RDFN 02-25-2025
- GYRE 11-13-2024
- Dividend Yield
- RDFN N/A
- GYRE N/A
- EPS Growth
- RDFN N/A
- GYRE N/A
- EPS
- RDFN N/A
- GYRE N/A
- Revenue
- RDFN $1,016,774,000.00
- GYRE $105,033,000.00
- Revenue This Year
- RDFN $8.63
- GYRE $25.32
- Revenue Next Year
- RDFN $9.90
- GYRE $12.95
- P/E Ratio
- RDFN N/A
- GYRE N/A
- Revenue Growth
- RDFN 3.70
- GYRE N/A
- 52 Week Low
- RDFN $5.10
- GYRE $8.26
- 52 Week High
- RDFN $15.29
- GYRE $27.10
- Technical
- Relative Strength Index (RSI)
- RDFN 42.16
- GYRE 38.46
- Support Level
- RDFN $7.69
- GYRE $10.39
- Resistance Level
- RDFN $8.20
- GYRE $12.85
- Average True Range (ATR)
- RDFN 0.43
- GYRE 1.17
- MACD
- RDFN -0.02
- GYRE -0.01
- Stochastic Oscillator
- RDFN 35.81
- GYRE 1.26
About RDFN Redfin Corporation
Redfin Corp is a residential real estate broker. It pairs its agents with the technology to create a service that is faster and costs less. The company meets customers through a listings-search website and mobile application. The company uses the same combination of technology and local service to originate mortgage loans and offer title and settlement services. It has five operating segments and three reportable segments, real estate services, rentals, and mortgage. The company generates the majority of its revenue from Real estate services.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.